Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.10/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.10/Share

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results

March 24, 2016 4:05 PM EDT

BERKELEY HEIGHTS, N.J., March 24, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP); "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2015.

The Companys net loss applicable to common shareholders for the fourth quarter ended December 31, 2015 was $3.4 million, or $0.10 per basic and diluted share,... More